About us
Aptarion Biotech develops new treatments for life-threatening diseases by leveraging the unique properties of mirror-image L-aptamers. Aptarion’s lead drug candidate AON-D21 is currently being tested in a Phase 2 clinical trial in 100 patients diagnosed with severe community-acquired pneumonia.
L‑Aptamers are single-stranded L-RNA or L-DNA molecules designed to bind and inhibit pharmacologically relevant targets comparable to monoclonal antibodies. They combine high target affinity, specificity, biostability and low immunogenicity with the ease of a scalable chemical production process.
Aptarion is headquartered in Berlin, Germany.
